Short-Term Outcome and MRI Changes in Three Adult Patients with Sickle Cell Disease and Aseptic Osteonecrosis after Treatment with Hyperbaric Oxygen Therapy: A Preliminary Report.

Avascular necrosis of bone Hyperbaric oxygen Sickle cell disease

Journal

Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601

Informations de publication

Date de publication:
Historique:
received: 29 01 2020
accepted: 30 01 2020
entrez: 2 5 2020
pubmed: 2 5 2020
medline: 2 5 2020
Statut: epublish

Résumé

Musculoskeletal manifestations are common in sickle cell disease (SCD). Vaso-occlusive crisis can manifest acutely as joint and bone pain, osteomyelitis and/or arthritis. It can also lead to chronic bone aches, bone deformities, degenerative arthritis, pathological fractures, and osteoporosis. Hyperbaric oxygen (HBO) therapy is a mode of treatment in which the patient is exposed to very high arterial and tissue oxygen pressure, during multiple sessions. It has been used as primary or adjunctive therapy for a variety of medical disorders, including necrotizing infection and sickle cell crisis. In this case series, 3 patients with SCD and avascular necrosis were treated with 15-40 sessions of HBO and were assessed 6-12 months by MRI after treatment. They showed different clinical outcomes and MRI changes. We concluded that HBO can result in some subjective improvement, especially in early stages. Further studies on severe cases are needed.

Sections du résumé

BACKGROUND BACKGROUND
Musculoskeletal manifestations are common in sickle cell disease (SCD). Vaso-occlusive crisis can manifest acutely as joint and bone pain, osteomyelitis and/or arthritis. It can also lead to chronic bone aches, bone deformities, degenerative arthritis, pathological fractures, and osteoporosis. Hyperbaric oxygen (HBO) therapy is a mode of treatment in which the patient is exposed to very high arterial and tissue oxygen pressure, during multiple sessions. It has been used as primary or adjunctive therapy for a variety of medical disorders, including necrotizing infection and sickle cell crisis.
CASE REPORT METHODS
In this case series, 3 patients with SCD and avascular necrosis were treated with 15-40 sessions of HBO and were assessed 6-12 months by MRI after treatment. They showed different clinical outcomes and MRI changes.
CONCLUSION CONCLUSIONS
We concluded that HBO can result in some subjective improvement, especially in early stages. Further studies on severe cases are needed.

Identifiants

pubmed: 32355491
doi: 10.1159/000506330
pii: cro-0013-0365
pmc: PMC7184821
doi:

Types de publication

Case Reports

Langues

eng

Pagination

365-372

Informations de copyright

Copyright © 2020 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors declare no potential conflicts of interest concerning the research, authorship, and/or publication of this article.

Références

Thromb Haemost. 2004 May;91(5):1047-9
pubmed: 15116269
Joint Bone Spine. 2006 Oct;73(5):500-7
pubmed: 16931094
Int Orthop. 2011 Apr;35(4):465-73
pubmed: 20182877
Rev Rhum Mal Osteoartic. 1990 Oct;57(9):669-70
pubmed: 2075407
Undersea Hyperb Med. 2002 Spring;29(1):1-3
pubmed: 12507181
EFORT Open Rev. 2019 Mar 15;4(3):85-97
pubmed: 30993010
J Wound Ostomy Continence Nurs. 1999 Mar;26(2):98-104
pubmed: 10373866
Ortop Traumatol Rehabil. 2012 Mar-Apr;14(2):155-60
pubmed: 22619100
Turk J Haematol. 2012 Sep;29(3):270-3
pubmed: 24744672
Invest Ophthalmol Vis Sci. 1985 Aug;26(8):1155-8
pubmed: 4019106
J Arthroplasty. 2010 Sep;25(6 Suppl):118-23
pubmed: 20637561
Klin Padiatr. 2004 Nov-Dec;216(6):370-8
pubmed: 15565553
World J Orthop. 2015 Nov 18;6(10):776-82
pubmed: 26601059
Orthopedics. 2015 Mar;38(3):e200-5
pubmed: 25760507
Diving Hyperb Med. 2012 Jun;42(2):82-4
pubmed: 22828815
J Glob Oncol. 2018 Sep;4:1-11
pubmed: 30241233
Int Orthop. 2018 Jul;42(7):1527-1534
pubmed: 29582115
Clin Orthop Relat Res. 2001 May;(386):173-8
pubmed: 11347831
Orthopade. 2017 May;46(5):440-446
pubmed: 27928615
J Med Case Rep. 2014 Nov 17;8:370
pubmed: 25399776
BMC Musculoskelet Disord. 2014 Feb 25;15:56
pubmed: 24568330
J Bone Joint Surg Br. 1995 Jan;77(1):34-41
pubmed: 7822393
J Bone Joint Surg Br. 2005 Apr;87(4):560-4
pubmed: 15795211
J Bone Joint Surg Am. 2003 Mar;85(3):500-4
pubmed: 12637438
J Crit Care. 2008 Sep;23(3):295-300
pubmed: 18725032
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1501-1505
pubmed: 30274530
J Orthop Res. 2013 Nov;31(11):1839-44
pubmed: 23878004
N Engl J Med. 1991 Nov 21;325(21):1476-81
pubmed: 1944426

Auteurs

Amr Shier (A)

Department of Medical Education, Hamad General Hospital Doha, Doha, Qatar.

Mohamed Abdelrazek (M)

Department of Radiology, Hamad General Hospital Doha, Doha, Qatar.

Ashraf Soliman (A)

Division of Endocrinology, Department of Pediatrics, Hamad General Hospital Doha, Doha, Qatar.
Division of Endocrinology, Department of Pediatrics, Alexandria University Children's Hospital, Alexandria, Egypt.

Vincenzo De Sanctis (V)

Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy.

Ahmed Elsayed (A)

Department of Orthopedic Surgery, Hamad General Hospital Doha, Doha, Qatar.

Mohamed Abdulla (M)

Hematology Section/Medical Oncology (NCCCR), Hamad General Hospital Doha, Doha, Qatar.

Shehab Mohamed (S)

Hematology Section/Medical Oncology (NCCCR), Hamad General Hospital Doha, Doha, Qatar.

Khadra Yassin (K)

Hematology Section/Medical Oncology (NCCCR), Hamad General Hospital Doha, Doha, Qatar.

Ilham Bilal (I)

Department of Pediatrics, Hamad General Hospital Doha, Doha, Qatar.

Mohamed Yassin (M)

Hematology Section/Medical Oncology (NCCCR), Hamad General Hospital Doha, Doha, Qatar.

Classifications MeSH